Joanne Wang
26Patents
7h-index
20Co-inventors
65Inventor score
Filing activity: Mar 13, 2009 → Jul 15, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8198034B2 | Immuno-based botulinum toxin serotype A activity assays | Physics | 36 | Active |
| US8618261B2 | Immuno-based botulinum toxin serotype A activity assays | Physics | 24 | Active |
| US8455203B2 | Immuno-based retargeted endopeptidase activity assays | Physics | 16 | Active |
| US9249216B2 | Immuno-based botulinum toxin serotype A activity assays | Physics | 11 | Active |
| US8361789B2 | Cells useful for immuno-based Botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 11 | Active |
| US8455213B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 10 | Active |
| US8455247B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 9 | Active |
| US8501469B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 5 | Active |
| US8507271B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 5 | Active |
| US8455248B2 | Cells useful for immuno-based Botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 4 | Active |
| US8476068B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 3 | Active |
| US10703806B2 | Immuno-based botulinum toxin serotype A activity assays | Physics | 3 | Active |
| US10451621B2 | Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A | Physics | 3 | Active |
| US10345306B2 | Immuno-based retargeted endopeptidase activity assays | Physics | 3 | Active |
| US8691566B1 | Cells useful for immuno-based botulinum toxin serotype a activity assays | Emerging Cross-Sectional Technologies | 3 | Active |
| US10900967B2 | Immuno-based retargeted endopeptidase activity assays | Physics | 2 | Active |
| US9651553B2 | Immuno-based retargeted endopeptidase activity assays | Physics | 2 | Active |
| US9625447B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 2 | Active |
| US8476069B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 1 | Active |
| US8663983B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 0 | Active |
| US8663982B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 0 | Active |
| US8603813B2 | Cells useful for immuno-based botulinum toxin serotype A activity assays | Emerging Cross-Sectional Technologies | 0 | Active |
| US11332518B2 | Immuno-based botulinum toxin serotype A activity assays | Physics | 0 | Active |
| US11261240B2 | Immuno-based botulinum toxin serotype A activity assays | Physics | 0 | Active |
| US10912823B2 | Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.